Skip to main content
. Author manuscript; available in PMC: 2021 Feb 13.
Published in final edited form as: Nanomedicine. 2019 Mar 8;18:189–195. doi: 10.1016/j.nano.2019.02.021

Table 4.

Pathologic Response

CRLX101 dosing schedule Dose N pCR Moderate response Minimal response
Every other week 12 mg/m2 3 1 (33%) 2 (67%) 0
15 mg/m2 19* 3 (16%) 11 (58%) 5 (26%)

Weekly 12 mg/m2 3 0 3 (100%) 0
15 mg/m2 6 2 (33%) 2 (33%) 2 (33%)

Total 30 6 (19%) 17 (55%) 7 (23%)
*

One patient did not undergo a surgical resection, one had a local excision with moderate response.